Catalog No.
Product Name
Application
Product Information
Citations
-
PERK Inhibitor
PERK-IN-4 is a highly selective inhibitor of the protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), demonstrating an IC50 of 0.3 nM. This compound effectively modulates the PERK pathway, which is activated in response to various endoplasmic reticulum stresses associated with numerous disease states. PERK-IN-4 is valuable for research applications focused on cellular stress responses and potential therapeutic strategies in diseases linked to the unfolded protein response. -
PERK Inhibitor
HC-5404-Fu is a potent and orally active inhibitor of the protein kinase PERK, exhibiting an IC50 of 0.001 μM against human PERK. By blocking PERK activation induced by VEGFR-TKIs, HC-5404-Fu disrupts the adaptive stress response that typically enhances tumor survival. This compound enhances anti-angiogenic effects by inhibiting the formation of both newly formed and mature tumor blood vessels, particularly in renal cell carcinoma models. HC-5404-Fu is suitable for research focused on tumor biology and angiogenesis in renal cell carcinoma. -
PERK Inhibitor
PERK-IN-5 is a highly potent inhibitor of PERK (Protein kinase RNA-like endoplasmic reticulum kinase), demonstrating IC50 values of 2 nM and 9 nM for PERK and phosphorylated eIF2α, respectively. This compound is selectively and orally bioavailable, making it an advantageous tool for in vivo studies. PERK-IN-5 has been shown to significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft model, positioning it as a valuable reagent for cancer research focusing on the UPR (unfolded protein response) pathway. -
PERK Inhibitor
(S)-PERK-IN-5 is a selective inhibitor of the protein kinase PERK (PKR-like endoplasmic reticulum kinase), exhibiting an IC50 range of 0.101-0.250 μM. This compound plays a critical role in studies focused on the unfolded protein response and endoplasmic reticulum stress pathways. Its application is pertinent in exploring therapeutic strategies for diseases associated with protein misfolding and metabolic dysregulation. -
PERK Inhibitor
PERK-IN-3 is a highly selective inhibitor of the Protein Kinase R (PKR)-like ER kinase (PERK) with an IC50 value of 7.4 nM. This compound effectively modulates the unfolded protein response, promoting cell survival under ER stress. It is primarily utilized in research investigating the role of PERK in cellular stress pathways, cancer biology, and neurodegenerative diseases. -
PERK Inhibitor
PERK-IN-6 is a selective inhibitor of the Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK), exhibiting an IC50 value of 2.5 nM. This compound inhibits PERK-mediated signaling pathways, making it a valuable tool for investigating the role of ER stress and unfolded protein response in various cellular processes. PERK-IN-6 is suitable for research applications in studying diseases associated with dysregulated PERK activity, including neurodegeneration and cancer. -
Apoptosis Inducer
Glucobrassicin is an indole-based compound that acts as an apoptosis inducer by disrupting microtubule integrity in both plant and mammalian cells. Its primary biological activity includes the induction of programmed cell death in mammalian cancer cells, making it a valuable tool in cancer research. Additionally, Glucobrassicin demonstrates significant effects on plant growth, as it inhibits seed germination and root growth at elevated concentrations. This dual functionality makes Glucobrassicin relevant for studies in both oncology and plant biology. -
Nucleoside Metabolite
(R)-b-Aminoisobutyric acid is a nucleoside metabolite that serves as an effective amino donor. It plays a significant role in various biochemical pathways, making it valuable for studies on amino acid metabolism and nucleoside synthesis. This compound can be used in research applications focused on metabolic disorders and the regulation of nucleoside levels within cells. -
Anticancer Agent
BMY-25551 is a potent Mitomycin A analogue, exhibiting 8 to 20 times greater cytotoxicity compared to Mitomycin C in murine and human tumor cell lines. This compound is primarily investigated as an anticancer agent and shows potential in research related to cancer therapies and hematologic suppression. Its enhanced efficacy makes BMY-25551 a valuable tool for exploring mechanisms of tumor cell inhibition. -
MIF Inhibitor
MIF-IN-1 is a potent inhibitor of macrophage migration inhibitory factor (MIF), with a reported pIC50 of 6.87. This compound is designed to selectively inhibit MIF activity, which plays a critical role in various inflammatory and immune responses. MIF-IN-1 is suitable for research applications focused on inflammation, autoimmune diseases, and cancer biology, providing valuable insights into MIF-mediated pathways. -
D-DT Inhibitor
RGB097 is a potent inhibitor of D-dopachrome tautomerase (D-DT), demonstrating an IC50 value of 0.5 µM. This compound exhibits significant biological activity and has potential applications in cancer research, particularly in elucidating the role of D-DT in oncogenesis and tumor progression. -
MIF Inhibitor
MIF-IN-5 is a potent and reversible inhibitor of macrophage migration inhibitory factor (MIF), exhibiting a competitive mechanism of action. With an IC50 of 4.8 μM and a Ki value of 3.3 μM, it effectively disrupts MIF's biological activity. This compound is valuable for research applications involving inflammation, immune response modulation, and potential therapeutic strategies targeting various diseases associated with MIF dysregulation. -
MIF Inhibitor
HTS05585 is a selective inhibitor of macrophage migration inhibitory factor (MIF), demonstrating a Kd value of 0.29 μM via microscale thermophoresis and 0.32±0.01 μM confirmed by isothermal titration calorimetry. This compound effectively inhibits the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, from LPS-stimulated macrophages. HTS05585 is a valuable tool for studying inflammation-related diseases, particularly in the context of sepsis research. -
MIF tautomerase Inhibitor
TE-11 is a potent MIF tautomerase inhibitor, exhibiting an IC50 value of 5.63 μM. This compound effectively ameliorates CD-like colitis and reduces migration of MIF-induced eosinophils and neutrophils. Additionally, TE-11 prevents M1 polarization and the associated metabolic reprogramming, making it a valuable tool for research in inflammatory and autoimmune disorders. -
Apoptosis Inducer
Moracin G is an apoptosis inducer that acts as a kinase modulator and receptor ligand. It forms stable interactions with key proteins, including AKT1, COX2, and Estrogen receptor 1, while competitively inhibiting specific kinase activity. By binding to MELK, Moracin G disrupts cell cycle regulation, leading to the impairment of cancer cell survival and proliferation, as well as the induction of apoptosis. This compound is relevant in research focusing on periodontitis and breast cancer. -
MIF Inhibitor
4-IPP (4-Iodo-6-phenylpyrimidine) is a selective suicide substrate and irreversible inhibitor targeting macrophage migration inhibitory factor (MIF). This compound significantly impedes MIF activity, making it a valuable tool for research into inflammatory processes, cancer progression, and immune response modulation. Its ability to inhibit MIF provides insights into the underlying mechanisms of various pathologies, facilitating the development of therapeutic strategies. -
MIF Antagonist
MIF098 is a potent macrophage migration inhibitory factor (MIF) antagonist. It effectively inhibits the proliferation, migration, and fibrosis of pulmonary smooth muscle cells, making it a valuable tool in the study of immunoinflammatory diseases. Research applications include investigating mechanisms of pulmonary disorders and exploring potential therapeutic strategies for related conditions. -
MIF Inhibitor
ISO-92 is a selective inhibitor of migration inhibitory factor (MIF) with an IC50 of 550 nM. This compound effectively reduces inflammatory activity and demonstrates a dose-dependent inhibition of hypoxia-induced proliferation in the CCL-210 cell line. In mouse models of hypoxia, ISO-92 significantly decreases the thickness of the pulmonary vascular wall. Its unique mechanism makes ISO-92 a valuable tool for investigating inflammatory and neurological disorders. -
Antitumor Agent
Mitomycin A is an antitumor agent that exerts its effects primarily through DNA cross-linking, leading to inhibition of cell division. It has been shown to inhibit the spontaneous migration of mouse monocytes and reduce the production of Migration Inhibition Factor (MIF) by human lymphocytes. Mitomycin A is utilized in research focused on tumor biology and the mechanisms of cancer progression, providing insights into potential therapeutic strategies. -
MIF-directed PROTAC
MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. This compound facilitates the targeted degradation of MIF, offering potential utility in cancer research by modulating inflammatory responses associated with tumor progression. Its application may provide insights into therapeutic strategies for malignancies influenced by MIF signaling pathways. -
MIF-2 Inhibitor
4-CPPC is a potent and selective inhibitor of Macrophage Migration Inhibitory Factor 2 (MIF-2), demonstrating a Ki value of 33 µM. This compound exhibits reversible inhibition, showcasing a notable selectivity over MIF-1 with a Ki value of 431 µM. 4-CPPC is valuable for research applications aimed at elucidating the role of MIF-2 in inflammatory responses and other pathological conditions, making it a critical tool for studying MIF-related signaling pathways. -
MIF Inhibitor
RDR 03785 is a covalent inhibitor of Macrophage Migration Inhibitory Factor (MIF), exhibiting an IC50 of 0.36 μM. This compound demonstrates significant biological activity in modulating MIF-related pathways, making it a valuable tool in the study of inflammatory diseases and immune response regulation. Research applications include exploring MIF's role in various pathophysiological processes, as well as potential therapeutic interventions targeting MIF. -
MIF Inhibitor
MKA031 is a non-competitive inhibitor of macrophage migration inhibitory factor (MIF) with an IC50 value of 1.7 μM. This compound disrupts the interaction between MIF and AIF, impedes MIF nuclear translocation, and interferes with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced cell death. MKA031 is particularly useful for research applications focused on chronic hepatitis C virus infection and related cellular pathways. -
MIF2 Tautomerase Inhibitor
R110 is a potent competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase, exhibiting an IC50 of 15 μM. This compound is valuable for research into cancer biology, specifically in mechanisms related to tumor progression and immune modulation. By targeting MIF2, R110 offers potential insights into therapeutic strategies for cancer treatment. -
MIF2 Tautomerase Inhibitor
MIF2-IN-1 is a potent inhibitor of the MIF2 tautomerase, exhibiting an IC50 of 1.0 μM. This compound effectively suppresses the proliferation of non-small cell lung cancer cells by inducing cell cycle arrest through the deactivation of the MAPK signaling pathway. MIF2-IN-1 is a valuable tool for researching cancer biology and therapeutic strategies in oncology. -
MIF Inhibitor
MIF-IN-4 hydrochloride is a potent inhibitor of macrophage migration inhibitory factor (MIF), with an affinity corresponding to a pIC50 of 5.01-6. MIF is a crucial cytokine involved in regulating macrophage migration and immune responses. This compound is valuable for research applications focused on inflammation, immune modulation, and related pathways. -
MIF Inhibitor
MIF-IN-6 is a potent inhibitor of macrophage migration inhibitory factor (MIF), exhibiting an IC50 of 1.4 μM and a Ki value of 0.96 μM. This compound effectively attenuates MIF-induced ERK phosphorylation and inhibits the proliferation of A549 cells, making it valuable for studies related to cancer biology and inflammation. Its mechanism of action positions MIF-IN-6 as a significant tool for exploring MIF-related pathways and potential therapeutic interventions. -
NF-κB Inhibitor, GPx Inhibitor, HIV Replication Inhibitor
α-MSH (11-13) acetate is a selective melanocortin-1 receptor ligand that functions as an inhibitor of NF-κB, GPx activity, and HIV replication. It induces an acute elevation of intracellular calcium levels under certain costimulation or pathway inhibition conditions. This compound effectively suppresses TNF-α-induced NF-κB activation, inhibits colony formation of Staphylococcus aureus and Candida albicans, and demonstrates potential in the study of infections related to these pathogens, as well as in traumatic brain injury, corneal epithelial wounds, and inflammatory bowel disease research. -
ASK1 Inhibitor
CS17919 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 of 22.52 nM. This compound demonstrates significant anti-inflammatory and antifibrotic effects, making it a valuable tool for investigating metabolic-related kidney and liver diseases. Its oral bioavailability enhances its utility in preclinical studies aimed at understanding ASK1's role in disease mechanisms and potential therapeutic interventions. -
ASK1 Inhibitor
DDO3711 is a specific inhibitor of apoptosis signal-regulated kinase 1 (ASK1), exhibiting an IC50 of 164.1 nM while displaying minimal inhibition of ASK2 (IC50 > 20 μM). This compound functions by dephosphorylating phosphorylated ASK1 at threonine 838 through recruitment of the phosphatase PP5. DDO3711 demonstrates significant ASK1-dependent antiproliferative effects and shows promise in studies related to cancer by targeting abnormally phosphorylated oncoproteins. -
ASK1 Inhibitor
JT21-25 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 of 5.1 nM. This compound plays a crucial role in inhibiting apoptotic signaling pathways, making it valuable for research focused on cellular stress responses and apoptosis. JT21-25 is utilized in studies investigating the modulation of ASK1 activity in various disease models, particularly those related to neurodegenerative disorders and cancer. -
Mdm2 E3 Ligase Inhibitor
MEL24 is an inhibitor of the Mdm2 E3 ligase, which plays a critical role in regulating p53 protein levels. This compound significantly reduces cell survival and enhances sensitivity to DNA-damaging agents in a p53-dependent manner. MEL24 is primarily utilized in antitumor research, contributing to studies aimed at understanding and overcoming resistance in cancer therapies. -
MDM2 Ligand
(rel)-Nutlin carboxylic acid is an MDM2 ligand derived from Nutlin 3, targeting the MDM2 protein to inhibit its interaction with p53. This compound plays a crucial role in cancer research, particularly in the study of p53 pathway modulation and potential therapeutic interventions. It can also be utilized in the development of PROTACs when linked to other proteins, facilitating targeted protein degradation. -
MDM2 E3 Ligase Inhibitor
MEL23 is an MDM2 E3 ligase inhibitor that specifically targets the E3 ligase activity of the MDM2-MDMX complex. This compound effectively inhibits the ubiquitination of MDM2 and p53, leading to decreased viability in cells expressing wild-type p53. Additionally, MEL23 stabilizes MDM2 through a mechanism that does not involve p53 transcription, making it a valuable tool for research into cancer biology and therapeutic strategies targeting the p53 pathway. -
PPT1 Inhibitor
Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders. -
Apoptosis Inducer
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) targets apoptosis induction and acts as a catalyst in various biochemical reactions. This gold complex demonstrates significant lipoxygenase (LOX) inhibitory activity, leading to cell cycle arrest and apoptosis in cancer cells. Additionally, it catalyzes the peroxidation of linoleic acid and shows antiproliferative effects against breast cancer cell lines, contributing to its application in cancer research. A weak interaction with DNA may be involved in its mechanism of action, further highlighting its potential in therapeutic exploration. -
Caspase-3 Activator
Ru(acac)3 (Tris(acetylacetonato)ruthenium(III)) acts as a caspase-3 activator and apoptosis inducer. This compound demonstrates growth inhibitory effects on various cell lines in vitro, primarily by inhibiting DNA/RNA synthesis and inducing a mild, reversible S-phase cell cycle arrest. Ru(acac)3 is utilized in research focused on ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other oncological studies. -
Apoptosis Inducer
Lumichrome is a photodegradation product of riboflavin that acts as an apoptosis inducer. It has been shown to inhibit the growth of human lung cancer cells and induce apoptosis through a p53-dependent mechanism. Additionally, Lumichrome serves as an inhibitor of the AKT/β-catenin signaling pathway, highlighting its potential utility in cancer research and therapeutic studies. -
Apoptosis Inducer
Karanjin is a furanoflavonoid with a primary mechanism as an apoptosis inducer. It demonstrates significant anti-cancer, anti-inflammatory, anti-diabetic, and antioxidant activities, making it a valuable compound for various research applications. Additionally, Karanjin exhibits protective effects against ulcerative conditions and Alzheimer’s disease, as well as insect repellent and acaricidal properties. Its diverse biological activities make it a promising candidate for studies in cancer therapy, inflammation, and neuroprotection. -
SLC7A11 Inhibitor, GPX4 Inhibitor
Anti-NSCLC agent-2 (compound 6o) functions as a dual inhibitor of SLC7A11 and GPX4, key regulators of ferroptosis. By disrupting redox homeostasis and depleting glutathione levels, this compound facilitates the accumulation of lipid peroxides, leading to the induction of ferroptosis in non-small cell lung cancer (NSCLC) cells. Anti-NSCLC agent-2 is a valuable tool for research focused on understanding and targeting non-small cell lung cancer mechanisms. -
Apoptosis Inducer
4′-O-Methylglabridin is an apoptosis inducer that disrupts the cell cycle and exhibits antioxidant and cytotoxic activities against cancer cells. It has been shown to inhibit a range of cancer cell lines, including liver, breast, and colorectal cancers, by reducing phosphorylated Rb and p21 protein levels, leading to an accumulation of cells in the subG1 and G2/M phases. Furthermore, 4′-O-Methylglabridin triggers caspase-dependent apoptosis through the release of cytochrome C and activation of caspase-9. Its antioxidant properties also include the inhibition of lipid peroxidation and prevention of LDL oxidation. This compound is valuable for research in cancer biology and atherosclerosis. -
Sphingolipid
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid that primarily targets cellular sphingolipid pathways. It is known to induce cell cycle arrest in the G0/G1 phase, effectively inhibiting cell growth. This compound serves as a valuable tool for studying sphingolipid metabolism and its implications in cell cycle regulation and cancer research.
